Vera Therapeutics
VERA
171 hedge funds and large institutions have $1.92B invested in Vera Therapeutics in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 67 increasing their positions, 55 reducing their positions, and 23 closing their positions.
65% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 23
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
22% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 55
7% more funds holding
Funds holding: 160 → 171 (+11)
0.86% less ownership
Funds ownership: 97.73% → 96.87% (-0.86%)
13% less capital invested
Capital invested by funds: $2.21B → $1.92B (-$295M)
75% less call options, than puts
Call options by funds: $1.59M | Put options by funds: $6.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.7M |
| 2 |
Holocene Advisors
New York
|
+$23.4M |
| 3 |
SC
Samlyn Capital
New York
|
+$23.3M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$22.6M |
| 5 |
AG
Artal Group
Luxembourg
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$48.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$41.9M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$37.9M |
| 4 |
CC
Commodore Capital
New York
|
-$27.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.5M |
VERA Hedge Fund Activity: Q2 2024 in Review
171 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q2 2024, worth a combined $1.92B — down 13% from $2.21B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new VERA positions and 23 closed out — a net gain of 15 holders — while 67 added to existing stakes and 55 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $48.7M. The largest seller was Morgan Stanley, cutting an estimated $48.8M.
- 171 institutional investors held Vera Therapeutics (VERA) as of Q2 2024, up from 160 in Q1 2024.
- Funds reported $1.92B of Vera Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
- 38 funds opened new Vera Therapeutics positions in Q2 2024 and 23 closed out, a net change of +15 holders.
- The largest Vera Therapeutics buyer in Q2 2024 was T. Rowe Price Associates, an estimated $48.7M added.
- The largest Vera Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $48.8M sold.
Based on aggregated 13F filings for Q2 2024.